Back to search results

qDSA Blood Flow Measurement in Liver Embolization

This study is testing a new way to measure blood flow called quantitative digital subtraction angiography (qDSA) during liver embolization procedures. Liver embolization is a treatment that blocks blood flow to liver tumors. The qDSA technique aims to help doctors make sure the right amount of blood flow is reduced to the tumor by measuring it before, during, and after the procedure. We are looking for up to 20 participants who are at least 18 years old and are undergoing transarterial embolization (TAE), transarterial chemoembolization (TACE), or radioembolization for liver tumors. We will be looking to see if qDSA measurements show a steady decrease in blood flow to the liver artery during these procedures. The study is currently unclear on its recruitment status.

Study design
This is an interventional study planning to enroll up to 20 participants. It is not specified if it is randomized or blinded.
What's involved
You would have one study visit where qDSA and ultrasound Doppler images are taken before, during, and after your embolization procedure. Data will be collected for up to 6 months.
Compensation
Not stated in the trial record.
Follow-up
Data will be collected and processed for up to 6 months after your procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06971991

qDSA Blood Flow Measurement in Patients Undergoing TAE of the Liver

Recruiting
NAAges 18+InterventionalScreening
University of Wisconsin, Madison
~20 participants
Updated 2026-03-30 on ClinicalTrials.gov
What's tested:qDSA Blood Flow Measurement

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of patients in which qDSA measurements demonstrate successive reductions in hepatic arterial velocity at the pre-, mid-, and post-embolization time points
Measured over data collected pre-embolization, mid-embolization, and post-embolization (up to 1 hour), data processed retrospectively for this measure when data collection is complete (up to 6 months)

Conditions

Transarterial Embolism
Transarterial Chemoembolization
Radioembolization

Explore related trials

Liver Carcinoma

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Paul Laeseke, MD, PhD · PRINCIPAL_INVESTIGATOR · UW School of Medicine and Public Health

Who to contact

Radiology Coordinators
[email protected]
608-282-8349
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Give voluntary, written informed consent to participate in this study and willing to comply with study-related evaluation and procedure schedule

Exclusion

Pregnancy or breastfeeding
Patients with an acute kidney injury or stage IV or V chronic kidney disease (Cr greater than 2.4 or estimated glomerular filtration rate (eGFR) less than 30), unless anuric and on dialysis without expected return of renal function.
Patients with an iodinated contrast allergy who cannot be adequately premedicated to receive contrast as part of the embolization procedure.
Patients with a physical or psychological condition that would impair study participation.
The patient is judged unsuitable for study participation by the Investigator for any other reason

What this trial measures

  • Number of patients in which qDSA measurements demonstrate successive reductions in hepatic arterial velocity at the pre-, mid-, and post-embolization time pointsdata collected pre-embolization, mid-embolization, and post-embolization (up to 1 hour), data processed retrospectively for this measure when data collection is complete (up to 6 months)